Orchestra BioMed to Participate in Upcoming Institutional Investor Conferences
Orchestra BioMed (Nasdaq: OBIO) said management will attend two institutional investor conferences in March 2026: TD Cowen (March 2-4) and Barclays Global Healthcare (March 10-12).
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Orchestra BioMed (Nasdaq: OBIO) said management will attend two institutional investor conferences in March 2026: TD Cowen (March 2-4) and Barclays Global Healthcare (March 10-12). Fireside chats are scheduled for March 3 at 9:50am ET and March 11 at 8:00am ET, with webcasts available live and archived on the company’s investor relations site.
Details
News Market Reaction – OBIO
On Feb 19, the day this news came out, OBIO closed 0.50% below the previous close.
Data tracked by StockTitan Argus for the Feb 19 session.
Key Figures
- TD Cowen conference dates
- March 2–4, 2026
- TD Cowen 46th Annual Health Care Conference
- TD Cowen fireside chat time
- 9:50am ET
- Fireside chat on Tuesday, March 3rd
- Barclays conference dates
- March 10–12, 2026
- Barclays 28th Annual Global Healthcare Conference
- Barclays fireside chat time
- 8:00am ET
- Fireside chat on Wednesday, March 11th
- Current share price
- $4.00
- Price before conference participation announcement
- Price change 24h
- 4.17%
- Move ahead of the conference news timing
- 52-week range
- $2.20 – $5.98
- Positioning within past year trading range
- Market capitalization
- $216,824,567
- Equity value prior to the announcement
Historical Context
-
Stock options for 120,000 shares granted to nine new employees.
-
Company expects up to $21M cash from Vivasure sale to Haemonetics.
-
Vivasure acquired by Haemonetics in a milestone-based transaction.
-
Multiple ICI meeting talks on AVIM Therapy and Virtue SAB program.
-
Stock options for 151,250 shares granted to 12 new employees.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW HOPE, Pa., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through strategic partnerships with market-leading global medical device companies, today announced that company management will participate in multiple upcoming institutional investor conferences. Details on the Company’s participation appear below:
TD Cowen 46th Annual Health Care Conference – March 2-4, 2026 (Boston, MA)
Management will participate in a live fireside chat at 9:50am ET on Tuesday, March 3rd and will also host one-on-one meetings with investors. The event will be accessible to investors and interested parties via a live webcast, which will be available live via this link, as well as after the event on Orchestra BioMed’s Investor Relations website.
Barclays 28th Annual Global Healthcare Conference – March 10-12, 2026 (Miami, FL)
Management will participate in a live fireside chat at 8:00am ET on Wednesday, March 11th and will also host one-on-one meetings with investors. The event will be accessible to investors and interested parties via a live webcast, which will be available live via this link, as well as after the event on Orchestra BioMed’s Investor Relations website.
About Orchestra BioMed
Orchestra BioMed is a biomedical innovation company accelerating high-impact technologies to patients through strategic collaborations with market-leading global medical device companies. The Company’s two flagship product candidates - Atrioventricular Interval Modulation (AVIM) Therapy and Virtue® Sirolimus AngioInfusion™ Balloon (Virtue SAB) - are currently undergoing pivotal clinical trials for their lead indications, each representing multi-billion-dollar annual global market opportunities. AVIM Therapy is a bioelectronic treatment for hypertension, the leading risk factor for death worldwide, and is designed to be delivered as a firmware upgrade to a pacemaker and achieve immediate, substantial and sustained reductions in blood pressure in patients with hypertensive heart disease. The Company has a strategic collaboration with Medtronic, one of the largest medical device companies in the world, for the development and commercialization of AVIM Therapy for the treatment of uncontrolled hypertension in pacemaker-indicated patients. AVIM Therapy has FDA Breakthrough Device Designation for these patients, as well as an estimated 7.7 million total patients in the U.S. with uncontrolled hypertension despite medical therapy and increased cardiovascular risk. Virtue SAB is a highly differentiated, first-of-its-kind non-coated drug delivery angioplasty balloon system designed to deliver a large liquid dose of proprietary extended-release formulation of sirolimus, SirolimusEFR™, for the treatment of atherosclerotic artery disease, the leading cause of mortality worldwide. Virtue SAB has been granted Breakthrough Device Designation by the FDA for the treatment of coronary ISR, coronary small vessel disease and below-the-knee peripheral artery disease. For further information about Orchestra BioMed, please visit www.orchestrabiomed.com, and follow us on LinkedIn.
Investor Contact:
Silas Newcomb
Orchestra BioMed
Snewcomb@orchestrabiomed.com
Media Contact:
Kelsey Kirk-Ellis
Orchestra BioMed
kkirkellis@orchestrabiomed.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.